Also known as: Coronavirus Disease 2019 (SARS-CoV-2 Infection)
COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus. Symptoms can range from mild cold-like illness to severe pneumonia.
COVID-19 is an infectious disease caused by the SARS-CoV-2 coronavirus, first identified in Wuhan, China, in December 2019. Since its emergence, the virus has caused a global pandemic resulting in hundreds of millions of confirmed cases and millions of deaths worldwide. While the acute pandemic phase has transitioned to an endemic pattern, SARS-CoV-2 continues to circulate and evolve, producing new variants that may affect transmissibility, disease severity, and immune evasion.
The clinical spectrum of COVID-19 ranges enormously, from completely asymptomatic infection to critical illness with acute respiratory distress syndrome (ARDS) and multi-organ failure. Most people experience mild to moderate illness that resolves within 1-2 weeks, but a significant minority develop severe disease requiring hospitalization. The virus primarily targets the respiratory system but can affect virtually every organ system, including the cardiovascular, neurological, gastrointestinal, and renal systems.
A distinguishing feature of COVID-19 is the phenomenon of long COVID (post-acute sequelae of SARS-CoV-2 infection), in which symptoms persist or new symptoms develop weeks to months after the initial infection. Long COVID affects an estimated 10-30% of infected individuals and can include fatigue, cognitive dysfunction, shortness of breath, and numerous other symptoms. Vaccination has been shown to significantly reduce the risk of severe disease, hospitalization, death, and to some degree, long COVID, and remains a cornerstone of the public health response alongside antiviral treatments.
People with COVID-19 often experience the following symptoms.
Fever is one of the most common COVID-19 symptoms, typically appearing 2-14 days after exposure. The fever pattern can be intermittent and may persist for several days. Chills often accompany or precede fever episodes.
A persistent, nonproductive cough is a hallmark symptom that can range from mild to severe. The cough results from inflammation of the airways and can persist for weeks after other symptoms resolve. In some cases, it may become productive as the illness progresses.
Anosmia (loss of smell) and ageusia (loss of taste) were among the most distinctive COVID-19 symptoms, particularly with earlier variants. These symptoms can occur suddenly, sometimes as the only manifestation of infection, and typically resolve within weeks but may persist for months in some individuals.
Profound fatigue is one of the most prevalent and debilitating symptoms, affecting up to 80% of symptomatic patients. It can range from mild tiredness to severe exhaustion that limits daily activities and may be one of the longest-lasting symptoms.
Dyspnea typically develops 5-10 days after symptom onset and can indicate progression to more serious disease involving the lungs. Mild breathlessness with exertion is common, but shortness of breath at rest is a warning sign requiring medical evaluation.
Generalized myalgia and arthralgia are common, affecting the back, legs, and arms. These aches result from the systemic inflammatory response to the viral infection and typically resolve as the acute illness improves.
Headache occurs in approximately 50-70% of symptomatic patients. Some individuals also experience difficulty concentrating, mental fogginess, or confusion, collectively termed 'brain fog,' which can persist as part of long COVID.
Nausea, vomiting, diarrhea, and abdominal pain occur in approximately 10-20% of cases. These may sometimes be the presenting symptoms, particularly in children. The GI tract expresses ACE2 receptors that the virus uses for cellular entry.
Certain factors may increase your likelihood of developing COVID-19.
Common approaches to managing covid-19. Always consult a healthcare provider for personalized treatment.
Nirmatrelvir/ritonavir (Paxlovid) is a first-line oral antiviral treatment for mild to moderate COVID-19 in patients at high risk for severe disease. It should be started within 5 days of symptom onset. Remdesivir (Veklury) is an intravenous antiviral used for hospitalized patients or high-risk outpatients.
Over-the-counter medications including acetaminophen or ibuprofen for fever and pain, dextromethorphan for cough, and antihistamines or decongestants for nasal symptoms can help manage mild illness. Adequate rest, hydration, and monitoring are essential.
Monoclonal antibodies targeting the SARS-CoV-2 spike protein have been used in high-risk patients to prevent progression to severe disease. However, their effectiveness depends on activity against circulating variants, and availability changes as new variants emerge.
Severe COVID-19 may require supplemental oxygen, dexamethasone (a corticosteroid that reduces inflammation), anticoagulation therapy to prevent blood clots, and in critical cases, mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Patients experiencing long COVID may benefit from multidisciplinary rehabilitation including pulmonary rehabilitation, cognitive therapy, graded exercise programs, and management of specific persistent symptoms. Long COVID clinics provide coordinated care for complex cases.
Proning (lying face down) can improve oxygenation in patients with COVID-19 pneumonia, both in hospital and home settings. Breathing exercises, including incentive spirometry and pursed-lip breathing, support respiratory recovery.
COVID-19 is diagnosed using a combination of clinical evaluation, epidemiological context, and laboratory testing. The gold standard for acute diagnosis is a molecular test (RT-PCR or nucleic acid amplification test) performed on a nasopharyngeal or nasal swab, which detects viral genetic material with high sensitivity and specificity. Rapid antigen tests provide results within 15-30 minutes and are widely available for home and point-of-care use, though they are less sensitive than molecular tests, particularly in early infection or asymptomatic individuals. Serological (antibody) tests detect prior infection or immune response to vaccination but are not used for acute diagnosis. Chest imaging including X-ray and CT scan may show characteristic patterns of ground-glass opacities in patients with pulmonary involvement and can help assess disease severity.
Seek emergency medical care immediately if you experience difficulty breathing, persistent chest pain or pressure, new confusion or inability to stay awake, or bluish lips or face. These are signs of severe COVID-19 that may require hospitalization. Also contact your doctor if mild symptoms suddenly worsen, especially around days 5-10 of illness, as this can signal progression to more serious disease. High-risk individuals should consult a healthcare provider early for potential antiviral treatment.
Steps that may help reduce the risk of developing or worsening covid-19.
Stay up to date with recommended COVID-19 vaccinations and boosters, which significantly reduce the risk of severe disease, hospitalization, and death
Practice good hand hygiene and consider wearing a well-fitting mask in crowded indoor settings during periods of high community transmission
Improve indoor ventilation by opening windows, using air purifiers with HEPA filters, and maximizing fresh air circulation in shared spaces
Test for COVID-19 if you develop symptoms or have a known exposure, and isolate from others if you test positive to prevent further transmission
Maintain overall health through regular exercise, adequate sleep, balanced nutrition, and management of chronic conditions to reduce the risk of severe outcomes
If left untreated or poorly managed, covid-19 may lead to:
Most people with COVID-19 are most contagious in the 1-2 days before and 2-3 days after symptoms begin. The infectious period generally lasts about 5-10 days from symptom onset for most individuals with mild to moderate illness. Immunocompromised individuals may remain infectious for longer periods. Using rapid antigen tests can help determine ongoing infectiousness, as a positive antigen test generally correlates with the presence of viable virus.
Yes, reinfection with SARS-CoV-2 is common, particularly as new variants emerge that partially evade immunity from prior infection or vaccination. Each reinfection can range from milder to equivalent or occasionally more severe than previous infections. Hybrid immunity (from both vaccination and natural infection) provides broader protection, but it wanes over time, which is why updated boosters are recommended.
Long COVID refers to symptoms that persist or develop more than 4 weeks after initial SARS-CoV-2 infection. It can include fatigue, brain fog, shortness of breath, heart palpitations, joint pain, and many other symptoms across multiple organ systems. Risk factors include severe initial illness, female sex, older age, obesity, pre-existing conditions, and being unvaccinated. Vaccination before infection appears to reduce the risk of developing long COVID.
Paxlovid (nirmatrelvir/ritonavir) is recommended for people at high risk for severe COVID-19, including those over 50, immunocompromised individuals, and those with certain underlying conditions. It must be started within 5 days of symptom onset to be effective. However, Paxlovid interacts with many common medications, so your doctor needs to review your current medications before prescribing it. Discuss with your healthcare provider whether you qualify and whether it is safe given your medication profile.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.